Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Obeticholic acid reversed NASH liver fibrosis in phase 3 trial

Publish date:: April 12, 2019

Key clinical point: Obeticholic acid is the first drug to have a beneficial impact on nonalcoholic steatohepatitis patients in a phase 3 trial.

Major finding: Liver fibrosis regressed in 23% of patients on 25 mg obeticholic acid daily and in 12% of control patients.

Study details: REGENERATE, an international, phase 3 trial with 931 patients.

Disclosures: REGENERATE was sponsored by Intercept, the company that markets obeticholic acid (Ocaliva). Dr. Younossi is a consultant to and has received research funding from Intercept. He has also been a consultant to Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Novartis, Novo Nordisk, Quest, Siemens, Terns Pharmaceutical, and Viking Therapeutics. Dr. Newsome has been a consultant or speaker for Intercept as well as Boehringer Ingelheim, Dignity Sciences, Johnson & Johnson, Novo Nordisk, and Shire, and he has received research funding from Pharmaxis and Boehringer Ingelheim.

Citation:

REPORTING FROM ILC 2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

Empagliflozin cut PA pressures in heart failure patients,